Although much is known with regard to the PK of many drugs, and many technologies have been established for PK research, recent studies are revealing the existence of new mechanisms by which how drugs are metabolized and how PK is regulated. New experimental models and computational modeling algorithms are arising for an improved understanding of the significance of PK in a whole-body system; nonetheless, many challenges remain. Drug metabolism is an important process for the removal of unwanted substances from the body. Abnormal drug metabolism profile could lead to life-threatening complications. Both phase I (mainly CYP450s) and phase II (mainly UGTs) enzymes play a significant role in drug metabolism.
1. Conventional transgenic animal models for DMPK research
DMPK research is essential for understanding the efficacy and safety of medications. Integrated studies on drug-metabolizing enzymes and transporters underlying the ADME processes as well as their transcriptional and posttranscriptional regulation mechanisms provide a comprehensive understanding of interindividual variations in pharmacotherapy. Future studies in these areas will undoubtedly advance our understanding to achieve better prediction of PK properties. Understanding the DDIs and disease–drug interactions is clinically important as such interactions may increase the risk of adverse reactions or lead to treatment failure. Although DDIs between small molecule drugs are relatively well-characterized, other potential interactions are not fully explored, including interactions with herbal biologics and other new forms of therapeutics.
Clinical Significance
Drug molecules which contain reducible groups like nitro, azo, alkene, aldehydes, and ketones easily undergo the process of reduction. The process of reduction is catalysed by specific enzymes which catalyse the reduction for specific classes. Aldo-keto reductases are required for the reduction of aldehydes and ketones.
Data availability
(D) Computationally modeled structures for terfenadine and its + O metabolite illustrating the structural compaction in the metabolite relative to the parent compound. Adapted with permission from Ross et al., 2019 [48]; Copyright (2019) American Chemical Society.. Examples of common Phase I (functionalization) and Phase II (conjugation) biotransformations that occur in drug metabolism. In addition to gene polymorphisms, epigenetic mechanisms, such as DNA methylation, which can regulate expression of CYP genes by targeting either the promoter region or upstream transcriptional factors, can also affect the variability of CYPs [49,57]. DNA methylation can influence the expression of some CYP genes, especially those involved in the metabolism of endogenous compounds [57,58].
Structures of CYPs
Although evidence of gut microbiota-mediated DDIs remain limited, the growing interest in microbiota will definitely provide a better understanding on their influence on the PK and pharmacodynamics of drugs. Nevertheless, the impact of herbal medicine on the gut microbiome is unavoidable, and such research is expected to provide more in-depth understanding on herb–drug interactions. In summary, in addition to consideration of classical PK and pharmacodynamic interactions, microbiota-mediated drug–drug/herb–drug interactions are expected to bring additional insight into their therapeutic effects. Due to the distinct pharmacokinetic and pharmacodynamic properties of therapeutic biologics, the classic approach for DDIs prediction for small molecules may not applicable for therapeutic biologics.
VI Metabolites of Study Drugs
- The ability of IM-MS to examine gas-phase structures makes it an excellent technique for the characterization of drug metabolites.
- Drugs can be also conjugated with glutathione or glycine, or modified by the transfer of methyl, acetyl, or sulpha groups from donor compounds.
- As it is difficult to obtain and culture embryonic stem cells in rats, the construction and application of knockout or knock-in rat models have lagged behind the mouse models.
The classes of pharmaceutical drugs that utilize this method for their metabolism include phenothiazines, paracetamol, and steroids. If the metabolites of phase I reactions are sufficiently polar, they may be readily excreted at this point. However, many phase I products are not eliminated rapidly and undergo a subsequent https://sober-house.org/chronic-relapsing-disease-finding-treatment-for/ reaction in which an endogenous substrate combines with the newly incorporated functional group to form a highly polar conjugate. Metabolic syndrome (MetS) is a cluster of medical conditions and risk factors correlating with insulin resistance that increase the risk of developing cardiometabolic health problems.
Among the three OCTs, OCT2 is the major transporter for renal secretion of a variety of drugs such as memantine, metformin and amantadine. For example, through inhibiting OCT2, cimetidine decreases the renal excretion of metformin and increases its plasma concentration99. On the other hand, OCT2, by modulating the exposure of drugs to renal proximal tubule cells alcohol-medication interactions regulates the nephrotoxicity of anticancer drug cisplatin and its analogs100. Substrates taken up from the systemic circulation may subsequently undergo efflux across the brush border membrane of proximal tubule cells by various ABC efflux transporters such as P-gp and BCRP. For example, a probe P-gp substrate, methotrexate, is actively secreted into urine.
For example, the potentials and mechanisms of DDI between erlotinib and docetaxel was studies by using Cyp3a1/2 KO rats320. Docetaxel significantly increased the maximum concentration and systemic exposure of erlotinib in wild type (WT) rats, but the DDI was significantly attenuated in Cyp3a1/2 KO rats, suggesting that the CYP3A plays the perpetrating role of docetaxel on erlotinib. In recent years, apart from the DDI, disease–drug interactions have attracted lots of attention due to their potential impact on efficacy and safety of clinical therapy. Disease–drug interactions mainly refer to the disease itself can lead to changes in PK and pharmacodynamics of drugs, and also include the influence of alteration of endogenous substrates related to metabolism on disease status.
It is worth emphasizing that CYPs are the most abundant and significant, as well as diverse, drug-metabolizing enzymes, and they play important roles in clinical drug metabolism [15]. In this review, we mainly concentrated on human CYPs; early research about CYPs necessarily involved animal models, but the intention was always to understand the human systems in the context of enzymes catalyzing the observed transformations. We covered the structures of CYPs, which have been discovered continuously, since the first was identified in the early 1980s. The wealth of new structural information has been particularly useful for giving a better understanding of CYP dynamics and how their active site adapts to substrates of diverse sizes and shapes. Of particular interest is the varying responses of individual patients to administered pharmaceuticals; thus, interindividual variations of drug metabolism resulting from genetic and epigenetic variants, as well as environmental factors, were systematically summarized. Lastly, we outline the clinical implications and therapeutic benefits of CYPs.
For example, concomitant treatment with the immunosuppressant methotrexate can decrease the clearance of mAbs including golimumab164, adalimumab162, and infliximab165. Another indirect pharmacokinetic DDI mechanism is cytokine–CYP modulation. Several biologics with immunomodulatory effects may alter CYP activities via modulating the cytokine levels leading to the altered PK of co-administered small molecules that are substrates of the affected CYPs159,163,166. For instance, tocilizumab, which can induce CYP3A4 activity by decreasing interleukin 6 levels, was found to reduce simvastatin systemic exposure167.
We are a community of more than 103,000 authors and editors from 3,291 institutions spanning 160 countries, including Nobel Prize winners and some of the world’s most-cited researchers. Publishing on IntechOpen allows authors to earn citations and find new collaborators, meaning more people see your work not only from your own field of study, but from other related fields too. Open Access is an initiative that aims to make scientific research freely available to all. It’s based on principles of collaboration, unobstructed discovery, and, most importantly, scientific progression.
AADAC is identified as a lipase that is capable of hydrolyzing endogenous cholesterol ester326; however, it has been recently found to be responsible for some clinical drugs, such as prasugrel327 and vicagrel328. Different from clopidogrel, the thiolactone metabolite of vicagrel is formed via a rapid hydrolysis before intestinal absorption329. The first activation step for vicagrel was initially believed to be mediated only by human intestine CES-2 (CES2) until a recent finding showed that AADAC also contributed to vicagrel hydrolysis (Fig. 4B). The activation of the parent drug before entering the systemic circulation guarantees short onset time and avoidance of “clopidogrel resistance” attributed to CYP2C9 gene polymorphisms. On the other hand, early and appropriate antimicrobial treatment is the predominant intervening measure to decrease patient mortality227. In addition, it is likely to cause low blood protein symptoms in sepsis due to the increased capillary permeability, decreased hepatic albumin synthesis and a large number of infusions230.
Prior to clustering, each variable was normalised by subtracting its mean and dividing by its standard deviation. Clusters were selected based on where the dendrogram is cut at a height of 0.5 for serum, and 0.85 for urine bins, since the correlation https://sober-home.org/author/gary-jackson/ between the bins is higher (combining the metabolic effect with the effect of working with bins mentioned earlier). The definition of MetS has long been a subject of debate and lacks a universal consensus within the medical community [5, 6].